Evaluation of the Radial Artery Deviation And Reimplantation Technique for Primary Hemodialysis Access Creation
Condition(s) studied
Investigational drug(s) / intervention(s)
End-cephalic vein to side-radial artery fistula creation: * Circumferential dissection of the cephalic vein (4-5cm long) * Longitudinal arteriotomy (\~10mm) * End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture
RADAR fistula creation: * Dissection of the anterior-medial aspect of the cephalic vein (\~15mm) without grasping or clamping the venous wall * Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips * Ligation and section of the radial artery (distal) * Longitudinal venotomy (\~10mm) * End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture
Study summary
The Radial Artery Deviation And Reimplantation (RADAR) technique is a new approach for the construction of hemodialysis arteriovenous fistula. In this technique, the radial artery pedicle is deviated towards the minimally dissected cephalic vein at the wrist. The aim of this study is to compare the safety and efficacy of this technique with the traditional end-cephalic to side-radial arteriovenous fistula, currently used as a first line vascular access in hemodialysis patients.
The hypothesis is that the minimal dissection concept used in the RADAR inhibits venous juxta-anastomotic neointimal hyperplasia and stenosis, and lead to higher rates of maturation and patency.
Eligibility
Primary outcome measure(s)
- Primary patency rate of the access — at 12 months
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Polyclinique Notre Dame | Draguignan | France | |
| Aphm | Marseille | France | |
| CHU de Nice - Service de chirurgie vasculaire | Nice | France | |
| Polyclinique Les Fleurs | Ollioules | France |
More Centre Hospitalier Universitaire de Nice trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT02728817 on ClinicalTrials.gov ↗ ← All trials in France